Sign in / Join Now
ETFs & Funds
Abraxane P3 panc ca studies likely to be a bust. Trial began 3/09; near end of trial 9/11, had to add 210 pts to the study
Only logical reason to add more pts was that
data was weak; more pts were needed to raise
SPARC recently shown to be beneficial in prostate
Add a reply...
Latest StockTalks »
people get CELG breaking news and analysis by email alert.
Get email alerts on CELG »
Get latest price
From other sites
Commit To Purchase Celgene Corp. At $75, Earn 5.9% Using Options
at Nasdaq.com (Thu, 11:50AM)
Celgene (CELG) Q3 Earnings: What's in Store for the Stock?
at Zacks.com (Thu, 9:48AM)
Oral OTEZLA® ¿ (Apremilast) Receives Positive Nice Recommendation For Adults With Chronic Plaque Psoriasis
at TheStreet (Thu, 4:00AM)
Celgene Skips the Placebo, Fails Drug Development 101
at TheStreet (Wed, 7:28AM)
Celgene Corporation And Sage Bionetworks Announce Technology Collaboration To Develop Observational Study Using The Apple ResearchKit Framework
at TheStreet (Tue, 7:30AM)